Fibromyalgia syndrome (FMS) is a chronic pain syndrome. Previous analyses of untargeted metabolomics data indicated altered metabolic profile in FMS patients.
We report a semi-targeted explorative metabolomics study on the urinary metabolite profile of FMS patients; exploring the potential of urinary metabolite information to augment existing medical diagnosis.
All cases were females. Patients had a medical history of persistent FMS (n = 18). Control groups were first-generation family members of the patients (n = 11), age-related individuals without indications of FMS (n = 10), and healthy, young (18–22 years) individuals (n = 41). The biofluid investigated was early morning urine samples. Data generation was done through gas chromatography–mass spectrometry (GC–MS) analysis and data processing and analyses were performed using Matlab, R, SPSS and SAS software.
Quantitative analysis revealed the presence of 196 metabolites. Unsupervised and supervised multivariate analyses distinguished all three control groups and the FMS patients, which could be related to 14 significantly increased metabolites. These metabolites are associated with energy metabolism, digestion and metabolism of carbohydrates and other host and gut metabolites.
Overall, urinary metabolite profiles in the FMS patients suggest: (1) energy utilization is a central aspect of this pain disorder, (2) dysbiosis seems to prevail in FMS patients, indicated by disrupted microbiota metabolites, supporting the model that microbiota may alter brain function through the gut-brain axis, with the gut being a gateway to generalized pain, and (3) screening of urine from FMS is an avenue to explore for adding non-invasive clinical information for diagnosis and treatment of FMS.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
The clinical details on the patients, as well as the full complement of NMR metabolomics data, are available in the Supplementary Information of (Malatji et al. 2017).
American College of Rheumatology
Group of first-degree relatives of the patients
Group of healthy young subjects
Group of age-matched subjects but unrelated to the patients
Central nervous system
- EI and HP:
A general and a histidine-containing cytoplasmic phosphor-carrier bacterial protein system
- EII-AT, EII-BT and EII-CT:
Tagatose-specific B. licheniformis multi-domain membrane proteins
Enzyme Commission number
Fibromyalgia impact questionnaire
Functional pain syndromes
Gas chromatographic–mass spectrometric
Human metabolome database
Irritable bowel syndrome
In-house clinical questionnaire
National Institute of Standards and Technology
Proton nuclear magnetic resonance
Nuclear Technologies in Medicine and Biosciences Initiative
Principal components analysis
Partial least squares discriminant analysis
Phosphoenolpyruvate:carbohydrate phosphotransferase system
Predictive ability parameter
Small intestinal bacterial over-growth
Variable important in projection
Baumgart, D. C., & Carding, S. R. (2007). Inflammatory bowel disease: Cause and immunobiology. Lancet, 369(9573), 1627–1640.
Bennett, R. M., Friend, R., Jones, K. D., Ward, R., Han, B. K., & Ross, R. L. (2009). The revised fibromyalgia impact questionnaire (FIQR): Validation and psychometric properties. Arthritis Research & Therapy, 11(4), R120.
Bouatra, S., Aziat, F., Mandal, R., Guo, A. C., Wilson, M. R., Knox, C., et al. (2013). The human urine metabolome. PLOS ONE, 8(9), e73076.
Brown, G. K., Cromby, C. H., Manning, N. J., & Pollitt, R. J. (1987). Urinary organic acids in succinic semialdehyde dehydrogenase deficiency: Evidence of α-oxidation of 4-hydroxybutyric acid, interaction of succinic semialdehyde with pyruvate dehydrogenase and possible secondary inhibition of mitochondrial β-oxidation. Journal of Inherited Metabolic Disease, 10(4), 367–375.
Caboni, P., Liori, B., Kumar, A., Santoru, M. L., Asthana, S., Pieroni, E., et al. (2014). Metabolomics analysis and modeling suggest a Lysophosphocholines-PAF receptor interaction in fibromyalgia. PLoS ONE, 9(9), e107626.
Carabotti, M., Scirocco, A., Maselli, M. A., & Severi, C. (2015). The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Annals of Gastroenterology, 28(2), 203–209.
Clauw, D. J. (2014). Fibromyalgia: A clinical review. JAMA, 311(15), 1547–1555.
Clauw, D. J. (2015). Fibromyalgia and related conditions. Mayo Clinic Proceedings, 90(5), 680–692.
Clish, C. B. (2015). Metabolomics: An emerging but powerful tool for precision medicine. Molecular Case Studies, 1(1), a000588.
Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nature Reviews Neuroscience, 13(10), 701–712.
Cryan, J. F., & O’Mahony, S. M. (2011). The microbiome-gut-brain axis: From bowel to behavior. Journal of Neurogastroenterology and Motility, 23(3), 187–192.
Egloff, N., Von Känel, R., Müller, V., Egle, U. T., Kokinogenis, G., Lederbogen, S., et al. (2015). Implications of proposed fibromyalgia criteria across other functional pain syndromes. Scandinavian Journal of Rheumatology, 44(5), 416–424.
Foster, J. A., & Neufeld, K. A. (2013). Gut–brain axis: How the microbiome influences anxiety and depression. Trends in Neurosciences, 36(5), 305–312.
Ge, Y., Duan, Y., Fang, G., Zhang, Y., & Wang, S. (2009). Polysaccharides from fruit calyx of Physalis alkekengi var. francheti: Isolation, purification, structural features and antioxidant activities. Carbohydrate Polymers, 77(2), 188–193.
Hackshaw, K. V., Rodriguez-Saona, L., Plans, M., Bell, L. N., & Buffington, C. T. (2013). A bloodspot-based diagnostic test for fibromyalgia syndrome and related disorders. Analyst, 138(16), 4453–4462.
Hansen, J., Gulati, A., & Sartor, R. B. (2010). The role of mucosal immunity and host genetics in defining intestinal commensal bacteria. Current Opinion in Gastroenterology, 26(6), 564–571.
Henström, M., & D’Amato, M. (2016). Genetics of irritable bowel syndrome. Molecular and Cellular Neuroscience, 3(1), 7.
Högenauer, C., Hammer, H. F., Krejs, G. J., & Reisinger, C. (1998). Mechanisms and management of antibiotic-associated diarrhea. Clinical Infectious Diseases, 27(4), 702–710.
Isono, M., Nakanishi, I., Sasajima, K. I., Motizuki, K., Kanzaki, T., Okazaki, H., et al. (1968). 2-Keto-l-gulonic acid fermentation: Part I. Paper chromatographic characterization of metabolic products from sorbitol and l-sorbose by various bacteria. Agricultural Biological Chemistry, 32(4), 424–431.
Jackson, F., Georgakopoulou, N., Kaluarachchi, M., Kyriakides, M., Andreas, N., Przysiezna, N., et al. (2016). Development of a pipeline for exploratory metabolic profiling of infant urine. Journal of Proteome Research, 15(9), 3432–3440.
Jones, K. D., Gelbart, T., Whisenant, T. C., Waalen, J., Mondala, T. S., Iklé, D. N., et al. (2016). Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia. Clinical and Experimental Rheumatology, 34(2 Suppl 96), 89–98.
Kelker, N. E., Simkins, R. A., & Anderson, R. L. (1972). Pathway of l-sorbose metabolism in Aerobacter aerogenes. Journal of Biological Chemistry, 247(5), 1479–1483.
Kennedy, P. J., Cryan, J. F., Dinan, T. G., & Clarke, G. (2014). Irritable bowel syndrome: A microbiome-gut-brain axis disorder? World Journal of Gastroenterology, 20(39), 14105–14125.
Kundig, W., Ghosh, S., & Roseman, S. (1964). Phosphate bound to histidine in a protein as an intermediate in a novel phospho-transferase system. PNAS, 52(4), 1067–1074.
Legangneux, E., Mora, J. J., Spreux-Varoquaux, O., Thorin, I., Herrou, M., Alvado, G., et al. (2001). Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology, 40, 290–296.
Levine, J. S., & Burakoff, R. (2011). Extraintestinal manifestations of inflammatory bowel disease. Gastroenterology & Hepatology (NY), 7(4), 235–241.
Li, M., Wang, B., Zhang, M., Rantalainen, M., Wang, S., Zhou, H., et al. (2008). Symbiotic gut microbes modulate human metabolic phenotypes. PNAS, 105(6), 2117–2122.
Malatji, B. G., Meyer, H., Mason, S., Engelke, U. F., Wevers, R. A., van Reenen, M., et al. (2017). A diagnostic biomarker profile for fibromyalgia syndrome based on an NMR metabolomics study of selected patients and controls. BMC Neurology, 17(1), 88.
Mason, S., Moutloatse, G. P., van Furth, M. A., Solomons, R., van Reenen, M., Reinecke, C. J., et al. (2014). KEMREP: A new qualitative method for the assessment of an analyst’s ability to generate a metabolomics data matrix by gas chromatography–mass spectrometry. Current Metabolomics, 2(1), 15–26.
Mayer, E. A., & Tillisch, K. (2011). The brain-gut axis in abdominal pain syndromes. Annual Review of Medicine, 62, 381–396.
Mayer, E. A., Tillisch, K., & Gupta, A. (2015). Gut/brain axis and the microbiota. Journal of Clinical Investigation, 125(3), 926–938.
McFarland, L. V. (2014). Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: A systematic review. British Medical Journal Open, 4(8), e005047.
Medina, S., Domínguez-Perles, R., Ferreres, F., Tomás-Barberán, F. A., & Gil-Izquierdo, Á. (2013). The effects of the intake of plant foods on the human metabolome. Trends in Analytical Chemistry, 52, 88–99.
Meyer, H. P. (2002). Myofascial pain syndrome and its suggested role in the pathogenesis and treatment of fibromyalgia syndrome. Current Pain and Headache Reports, 6(4), 274–283.
Miquel, S., Leclerc, M., Martin, R., Chain, F., Lenoir, M., Raguideau, S., et al. (2015). Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. mBio, 6(2), e00300-15.
Moon, J. Y., Jung, H. J., Moon, M. H., Chung, B. C., & Choi, M. H. (2009). Heat-map visualization of gas chromatography-mass spectrometry based quantitative signatures on steroid metabolism. Journal of the American Society for Mass Spectrometry, 20(9), 1626–1637.
Murphey, W. H., & Rosenblum, E. D. (1964). Mannitol catabolism by Staphylococcus aureus. Archives of Biochemistry and Biophysics, 107(2), 292–297.
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., et al. (2012). Host-gut microbiota metabolic interactions. Science, 336(6086), 1262–1267.
Nicholson, J. K., Holmes, E., & Wilson, I. D. (2005). Gut microorganisms, mammalian metabolism and personalized health care. Nature Reviews Microbiology, 3(5), 431–438.
Pimentel, M., Chow, E. J., Hallegua, D., Wallace, D., & Lin, H. C. (2001). Small intestinal bacterial overgrowth: A possible association with fibromyalgia. Journal of Musculoskeletal Pain, 9(3), 105–113.
Postma, P. W., & Lengeler, J. W. (1985). Phosphoenolpyruvate: Carbohydrate phosphotransferase system of bacteria. Microbiological Reviews, 49(3), 232–269.
Russell, I. J., Orr, M. D., Littman, B., Vipraio, G. A., Alboukrek, D., Michalek, J. E., et al. (1994). Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis & Rheumatology, 37(11), 1593–1601.
Saier, M. H., Jr. (2015). The bacterial phosphotransferase system: New frontiers 50 years after its discovery. Journal of Molecular Microbiology and Biotechnology, 25(2–3), 73–78.
Shah, J. P., Phillips, T. M., Danoff, J. V., & Gerber, L. H. (2005). An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. Journal of Applied Physiology, 99(5), 1977–1984.
van der Heiden, E., Delmarcelle, M., Lebrun, S., Freichels, R., Brans, A., Vastenavond, C. M., et al. (2013). A pathway closely related to the d-tagatose pathway of Gram-negative enterobacteria identified in the Gram-positive bacterium Bacillus licheniformis. Applied and Environmental Microbiology, 79(11), 3511–3515.
van Schaik, W., & Willems, R. J. (2010). Genome-based insights into the evolution of enterococci. Clinical Microbiology & Infection, 16(6), 527–532.
Wallace, D. J., & Hallegua, D. S. (2004). Fibromyalgia: The gastrointestinal link. Current Pain and Headache Reports, 8(5), 364–368.
Willats, W. G. T., McCartney, L., Mackie, W., & Knox, J. P. (2001). Pectin: Cell biology and prospects for functional analysis. Plant Molecular Biology, 47(1–2), 9–27.
Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., et al. (2012). HMDB 3.0—The human metabolome database in 2013. Nucleic Acids Research, 41(D1), D801–D807.
Wolfe, F., Smythe, H. A., Yunus, M. B., Bennett, R. M., Bombardier, C., Goldenberg, D. L., et al. (1990). The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis & Rheumatology, 33(2), 160–172.
Yunus, M. B., Dailey, J. W., Aldag, J. C., Masi, A. T., & Jobe, P. C. (1992). Plasma and urinary catecholamines in primary fibromyalgia: A controlled study. Journal of Rheumatology, 19, 95–97.
Research funding for this project was provided by the Technological Innovation Agency (TIA) of the South African Department of Science and Technology (DST) and from the Nuclear Technologies in Medicine and the Biosciences Initiative (NTeMBI) of the Nuclear Energy Corporation of South Africa (NECSA). BM received a postgraduate bursary from the National Research Foundation (NRF) of South Africa.
Conflict of interest
The authors declare that there are no competing interests regarding the publication of this paper.
Ethical approval for the study was obtained via a consortium under the Nuclear Technologies in Medicine and Biosciences Initiative (NTeMBI) of South Africa and ethical approval by Pharma Ethics Pty, Ltd (Reference number 11064365). Pharma Ethics confirmed the following: “The study has been accepted as complying to the Ethics Standards for Clinical Research with a new drug in participants based on FDA, ICH GCP and the Declaration of Helsinki guidelines. The Ethics Committee (IRB) granting this APPROVAL is in compliance with the Guidelines for Good Practice in the Conduct of Clinical Trials in Human Participants in South Africa (2006), ICH Harmonised Tripartite Guidelines E6: Note: for the Guidance in Good Clinical Practice (CPMP/ICH/135/95) and FDA Code of Federal Regulation Part 50, 56 and 312.” Informed consent was obtained from all the participants in this study by means of a voluntarily completed consent form, included in the SI.
All authors have given their approval of the version of the manuscript as submitted, their consent for publication and agreed to the accountability requirements.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Malatji, B.G., Mason, S., Mienie, L.J. et al. The GC–MS metabolomics signature in patients with fibromyalgia syndrome directs to dysbiosis as an aspect contributing factor of FMS pathophysiology. Metabolomics 15, 54 (2019). https://doi.org/10.1007/s11306-019-1513-6
- Fibromyalgia syndrome (FMS)
- Gas chromatography–mass spectrometry (GC–MS)